Process Validation of Ointment Creams 2
Process Validation of Ointment Creams 2
Process Validation of Ointment Creams 2
History: Zinc oxide rash cream that was heated to a relatively high temperature solely by the action of rotating mixing plate.
Ointment
Soft, semisolid preparation intended for application to skin and mucus membrane.
Cream
Viscous emulsion of semisolid consistency intended for application to skin and mucus membrane.
Appearance: Opaque
Type: Oleaginous bases Absorption bases Emulsion bases Water soluble bases
Appearance: Translucent
Type: oil-in-water(o/w) water-in-oil(w/o)
Process Validation
Documented evidence, a high degree of assurance that a specific process will consistently produce a product that meets its predetermined specification and quality characteristics.
cont..
Process validation
WHY ENFORCE IT? WHEN IS IT PERFORMED?
WHO PERFORMS IT?
Why?
Makes good engineering sense. Results in fewer product recalls and troubleshooting assignments in manufacturing operations.
Results in more technically and economically sound products and their manufacturing processes.
When?
Development stage Product design 1X batch size Batch size
Product characterization
Formula selection Process design Product optimization Process characterization Process qualification Process demonstration Process validation program Product / process certification
1X
1X 1X 10x batch size 10X 10x 100X batch size 100x 100x
Who?
Formulation development Process development Pharmaceutical manufacturing Engineering QA QC API operations Regulatory affairs IT operations
ORDER OF PRIORITY
A. Sterile products and their processes(High Risk)
1) LVP 2) SVP 3) Ophthalmic, other sterile products and medical devices
Validation Protocol
Written plan describing the process to be validated, including production equipment. How validation will be conducted Objective test parameter Product characteristics Predetermine specification Factors affecting acceptable result
Cont..
Product qualification test data from prevalidation batches Test data from formal validation batches Sampling plan - where, when and how the samples to be taken Evaluation of test data, conclusion Any need for requalification and revalidation Certification and approval Summary report of finding with conclusion Copies of product stability
Revalidation
- change in critical component(raw material) - change or replacement in a critical piece of equipment. - change in a facility and/or plant - significant increase or decrease in batch size - sequential batches that fail to meet product and process specifications
Homogenize or pass thru colloid mill while warm. Cool slowly with counter sweep agitator
1. Mixing of Liquids
Equipment: Kettle and tank fitted with agitator
Process variables Capacity of unit Shape and position of agitation system Order of agitation Rate of addition Viscosity of liquid Appearance of liquid Potency Properties affected Monitoring Output by variables
Appearance pH
Capacity of unit Mixing speed of unit Shape of unit and Position of mixing elements within unit Product load Particle size of Potency solids Blend uniformity Particle size analysis Content uniformity
Homogeneity
Content uniformity
Viscosity Density
4. Dispersing
Equipment: Homogenizers, Colloid mill, or ultrasonic device
Process variables Properties affected by Monitoring variables output
Potency Particle size of solids Particle size distribution viscosity Specific gravity
Bore opening/ power setting Pressure/rotor speed/power consumption Feed rate Temperature Dispersion time Order of mixing
Viscosity of liquid
Product load
Feed rate
Inert atmosphere
Product testing
Validation testing of bulk and finished product must be based on testing standard release criteria and in process testing criteria Routine QC release testing should be performed on a routine sample. These samples should be taken separately from the validation samples. Validation sampling and testing typically is 3 to 6 time the usual QC sampling.
Sampling Plan
Samples must be representative of each filling nozzle.
Ten equidistant points across the filling run must be sampled. The beginning and end of filling must be represented.
Samples should be taken in triplicate.
Monitoring Output
1) Particle size Consideration
Control of particle morphology and particle size are important parameters to attain high quality drug product manufacture and control procedure.
Particle size distribution for most disperse system should be in the range of 0.2-20 microns.
2) Viscosity
The Viscometer- Calibrated to measure the apparent viscosity of the disperse system at equilibrium at a given temperature to establish system reproducibility.
Consistency type Soft, spreadable
Plastic flow, spreadable
Pharmaceutical example
W/O, O/W CREAM
Ointment
3) Content Uniformity
Most important parameter governing product stability and process control of the disperse system.
In ointment/cream formulation are more dependent on particle size, shear rate, and mixing efficiency in order to attain and maintain uniformity of the active drug component(usually the internal phase).
Monitoring Output
Sampling Plan
Content Uniformity
3 4 units from UPL & LPL within 90 beginning, 110% LA middle and end of filling cycle; RSD 4.2% total = 10 units
The average result of 10 individual results must meet the release limit for assay. The usual sample size for testing ranges between 0.5 and 1.5 g per sample assay.
4) Preservative effectiveness
Incorporating a USP antimicrobial preservative testing procedure or microbial limit test into formal validation of aqueous dispersion.
Determination of bio burden for validation and production batches can also be used to establish appropriate validated cleaning procedure for the facilities and equipment used in manufacture of disperse system.
5) Dissolution Testing:
It is primary used as a quality control procedure to determine product uniformity.
as a means of assessing the in vivo absorption of the drug in terms of a possible in vitro/vivo correlation.
For cream/ointments, the Franz in vitro flow through diffusion cell has been modified by using silicon rubber membrane barrier to stimulate percutaneous dissolution unit for testing purpose.
secondary
Validation Report
STANDARD FORMAT 1. Executive summary 2. Discussion 3. Conclusions & recommendation 4. List of attachment Topic should be presented in the order in which they appear in the protocol. Protocol deviation are fully explained & justified. The report is signed & dated by designated representatives of each unit involved in water system validation.
References
Lieberman H. A. , Rieger M. M. and Banker G. S. Pharmaceutical Dosage Forms: Disperse System ,vol.3; Second Edition,473-511
R. A. Nash and A. H. Wachter Pharmaceutical process validation; Third edition Agalloco James, Carleton J. Fredric Validation of Pharmaceutical Processes; Third edition,417-428
Thank You